Skip to content

Free cash flow at other companies

Eli Lilly logo
Eli LillyLLY
$3.01B+1,828%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$848.3M+4.0%
AbbVie logo
AbbVieABBV
$3.56B+155%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
Summit Therapeutics logo
Summit TherapeuticsSMMT

Other financials

Income statement

See full
Operating income-$82.8M-31.2%
Net income-$74.1M-33.9%
EPS (diluted)-$1.06-11.6%

Balance sheet

See full
Cash & equivalents$451.8M+323%
Total debt$8.0M-31.9%
Total assets$1.3B+81.1%

Cash flow

See full
Operating cash flow-$55.6M-14.6%
CapEx$62.0K

Valuation

See full
Market cap$6.81B+189%
Enterprise value$6.37B+181%

Returns & leverage

See full
Current ratio32.6×+16.8×

Where this comes from

Calculated from Apogee Therapeutics, Inc.’s reported figures.

The official record: Apogee Therapeutics, Inc.’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apogee Therapeutics, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Apogee Therapeutics, Inc.'s free cash flow?
Apogee Therapeutics, Inc. (APGE) reported free cash flow of -$62.75M in Q4 2025.
How has Apogee Therapeutics, Inc.'s free cash flow changed year-over-year?
Apogee Therapeutics, Inc.'s free cash flow increased by 7.3% year-over-year, from -$67.71M to -$62.75M.
What is the long-term trend for Apogee Therapeutics, Inc.'s free cash flow?
Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s free cash flow has grown at a 76.2% compound annual growth rate (CAGR), from -$74.93M to -$232.6M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.